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1Introduction
Every year, a large number of new cases of colorectal 
cancer are diagnosed in the world. Colorectal cancer is 
the third most common cancer and the fourth leading 
cause of cancer death worldwide [1]. Surgical intervention 
and chemotherapy represent the first- line strategy for the 
treatment of the majority of CRC patients [2]. However, 
the clinical outcome of CRC patients is significantly limited 
by the de novo or acquired chemoresistance, which con-
tributes to most cancer- related deaths. Tumor cells in 
fact, can become resistant to the drugs originally used to 
treat them and cross resistant to other drugs with dif-
ferent mechanisms of action leading to the appearance 
of a multidrug resistance (MDR) phenotype [3].
Several mechanisms have been suggested to mediate 
resistance to chemotherapeutic agents in colorectal cancer 
cells. One of the most studied mechanisms is the high 
expression of the human MDR1 gene and the 
P- glycoprotein (P- gp) transporter, encoded by MDR1 [4]. 
Pgp is a drug efflux pump, which decreases the intracel-
lular content of chemotherapeutic agents such as 
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Abstract
The major cause of failure in cancer chemotherapy is the development of 
 multidrug resistance (MDR), and the characterization of biological factors in-
volved in this response to therapy is particularly needed. A doxorubicin- resistant 
HCT- 8/R clone was selected from sensitive parental cells and characterized ana-
lyzing several parameters (cell cycle phase distribution, apoptotic activity, ex-
pression, distribution and functionality of the P- gp efflux pump, the response 
to other chemotherapy agents, its ultrastructural features, invasiveness, and 
transcriptomic profile). HCT- 8/R cells showed a peculiar S phase distribution, 
characterized by a single pulse of proliferation, resistance to drug- mediated 
apoptosis, increased expression and functionality of P- gp and overexpression of 
stem cell markers (CD44 and aldehyde dehydrogenase 1A2). At the ultrastruc-
tural level, HCT- 8/R presented a greater cell volume and several intracytoplasmic 
vesicles respect to HCT- 8. Moreover, the resistant clone was characterized by 
cross resistance to other cytotoxic drugs and a greater capacity for migration 
and invasion, compared to parental cells. Our data reinforce the concept that 
the MDR phenotype in HCT- 8/R cells is multifactorial and involves multiple 
mechanisms, representing an interesting tool to understand the biological basis 
of MDR and to test strategies that overcome resistance to chemotherapy.
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anthracyclines and its high expression in cancer cells is 
considered to be the major cause of MDR and the failure 
of chemotherapy [5].
In the last few years, several in vitro models of MDR 
in colon cancer cell lines have been developed in order 
to understand the biological processes underlying the 
onset of MDR phenotype and to test the novel thera-
peutic strategies to overcome this phenomenon. HCT- 8 
is a cell line derived from the ileocecal portion of the 
right colon and represents a less frequent cancer type 
compared to tumors of the left colon. Chen and cow-
orkers recently developed a HCT- 8 clone resistant to 
5- FU to evaluate the role of the tumor suppressor LIM 
domain- containing protein 1 (LIMD1) in chemoresist-
ance [6].
Besides the overexpression of efflux pumps, the MDR 
phenotype implicates the modulation of a large number 
of biological pathways, such as cell cycle, apoptosis, and 
DNA damage, which have not been investigated in detail.
In order to further characterize the MDR phenotype, 
we developed an in vitro model of HCT- 8- resistant 
colorectal cancer cell and investigated the aspects of 
morphology, efflux balance, invasion, migration 
together with global gene expression profiles. Given 
the complexity of MDR phenomenon, a careful char-
acterization of in vitro models could help to identify 
new biological processes involved in MDR and also 
to develop novel therapeutic strategies to overcome 
chemoresistance.
Materials and Methods
Cell culture
The HCT- 8 cell line was used as parental cell line [7] 
maintained in culture for many years in our laboratory. 
HCT- 8 cells were cultured in DMEM (Gibco Invitrogen, 
Carlsbad,CA) supplemented with 10% fetal bovine serum 
(Gibco Invitrogen), 100 U/mL penicillin–streptomycin, 
1% l- glutamine(200 mmol/L), and 4.5 g/L glucose, and 
grown in 5% CO2. Resistant HCT- 8 clone (HCT- 8/R) 
was established employing three steps selection with 
10 μM doxorubicin treatment for 24 h followed by 
culturing in drug- free medium. Briefly, 2 × 105 cells/
mL were seeded in 75 cm2 flask with drug. After 24 h 
of drug exposure, the cells were washed with serum- 
free medium and maintained in medium without drug. 
After 30 days, an individual cell clone was isolated and 
maintained in culture with addition of 10−8mol/L doxo-
rubicin (Sigma Aldrich, Milan, Italy). All experiments 
were performed with cells grown in the absence of 
doxorubicin for at least 4d to avoid drug- associated 
secondary effects.
Cell line identification
The cancer cell identification was performed using 
AmpFlSTR®Identifiler® Plus Kit (Life Technologies, Milan, 
Italy) in association with 3500 Genetic Analyzer and 
GeneMapper ID- X Software a standard DNA STR 
profiling.
CGH array
Genomic DNA was extracted by using the QiAmp tissue 
Kit (Qiagen, Hilden, Germany) and hybridized against 
Human Genome CGH 44k microarrays (Agilent 
Technologies, Palo Alto, CA), spanning the entire human 
genome at a median resolution of ~75 kb, according 
to the manufacturer’s protocols and using lymphocytes 
from healthy donor as reference. Images were scanned 
using the Agilent DNA microarray scanner (G2505B) 
and extracted using the Agilent Feature Extraction 
Software v9.5 (Agilent Technology, Santa Clara, CA). 
CGH feature Extraction files were loaded into CGH 
Analytics 3.5.14 software (Agilent Technologies) and 
analyzed for aberration calls, using the human genome 
sequence hg17 version and analyzed for aberration calls 
by selecting as follows: statistical algorithm ADM- 2, 
centralization on, fuzzy zero on, threshold at 6.0, aber-
ration filter set at 5 for the minimum number of probes 
in region and at 0.24 for the minimum absolute average 
log ratio for region. The Derivative Log Ratio Spread 
(DLRS) for the hybridization was 0.29.
Cell cycle analysis
For cell cycle analysis, parental (HCT- 8) and resistant (HCT- -
8/R) cells (1 × 106 cells/mL) were fixed, at 24, 48, and 72 h 
after seeding, in 70% ice- cold ethanol and stored at 4°C. 
Cells were stained by propidium iodide (PI) staining tech-
nique as described by Coronnello et al [8]. PI- stained cells 
were then analyzed on a FACSCanto flow cytometer. The 
fluorescence of PI was collected by a 620 nm band pass 
filter. Samples were gated on forward scatter versus side 
scatter to exclude cell debris and clumps. A minimum of 
10,000 events were collected for each sample and cell cycle 
distribution of cells was evaluated on linear scale by Cylchred 
Windows 95 software (http://www.uwem.ac.uk/study/medi-
cine/hematology/cytonetuk/documents/software.htm).
Cytotoxicity assay
HCT- 8 and HCT- 8/R were seeded in 96- well plates at a 
density of 5 × 103 cells/well in 100 μL of medium added 
of 10% FBS. After 24 h incubation at 37°C in 5% CO2, 
doxorubicin, 5- fluorouracil and oxaliplatin (Sigma Aldrich) 
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were added to the wells at a range of concentrations 
appropriate for each drug to a final volume of 200 μL/
well and incubated for 72 h at 37°C in 5% CO2. Cell 
growth was assessed by the colorimetric method based 
on [3- (4,5- dimethylthiazol- 2- yl)- 5- (3- carboxymethoxyphe
nyl)- 2- (4- sulfophenyl)- 2H- tetrazolium, inner salt; MTS] 
and an electron coupling reagent (phenazine ethosulfate; 
PES) (Promega Corporation, WI) The optical density of 
the chromogenic product was measured at 490 nm. IC50 
values were determined graphically from relative survival 
curves obtained by GraphPad Prism 5 software (GraphPad, 
San Diego, CA). The resistance index of HCT- 8/R was 
calculated to determine the degree of acquired resistance 
to doxorubicin and to other drugs. The resistance index, 
expressed as ratio between IC50 of HCT- 8/R in comparison 
with IC50 of parental cells, was calculated according to 
the expression:
R = IC50- resistant cell line/IC50- sensitive cell line
Transmission electron microscopy and 
immunoelectron microscopy
HCT- 8 and HCT- 8/R cells (106cells) were fixed in 4% 
glutaraldehyde (Elec- tron Microscopy Sciences, Hatfield, 
PA) in 0.1 mol/L cacodylate buffer, pH 7.4 for 8 h 
at 4°C. After fixation, for evaluation of their ultras-
tructure, cells were embedded in epoxy resin and rou-
tinely processed for transmission electron microscopy. 
For immunoelectron microscopy, after fixation, the 
cells were preincubated in 0.1% (v/v) Triton (Sigma 
Aldrich) and 1% (w/v) bovine serum albumin (Sigma 
Aldrich) in PBS for 15 min at room temperature. 
Samples were then incubated with 3% hydrogen per-
oxide to quench endogenous peroxidase and, succes-
sively, with primary antibody anti Human MDR- 1 
P- Glycoprotein (P- gp) (Chemicon Millipore 
Corporation, Billerica, MA, USA) at final dilution of 
1:20 overnight at 4°C. Immunoreaction was revealed 
by biotin- conjugated, polyclonal, rabbit anti- mouse 
antibody at a final dilution of 1:200 (Dako, Glostrup, 
Denmark), followed by incubation with streptavidin 
peroxidase complex (Thermo Scientific, Runcorn, 
Cheshire,UK) and with DAB kit Sigmafast™ 
3,3′- diaminobenzidine tablets (0.7 mg/mL DAB urea 
hydrogen peroxide mixture 1.6 mg/mLin 6 mmol/L 
Tris–HCl buffer (Sigma–Aldrich, St. Louis, MO, USA) 
for 5 min at room temperature. Successively, samples 
were embedded in epoxy resin and routinely processed 
for transmission electron microscopy. Sections cut on 
an ultramicrotome about 70 nm thick were examined 
at 80 kV in a Jeol 1010 transmission electron micro- 
scope (Jeol, Tokyo, Japan).
Percentage of polynucleolated cells
Semi- thin sections were obtained from samples prepared 
for electron transmission microscopy as described above. 
Sections were stained with toluidine blue and observed in 
a Leitz microscope (Leica Microsystems MicrosystemsGmbH, 
Wetzlar, Germany) equipped with an image capture sys- tem 
(ProgRes C10plus, Carl Zeiss, Göttingen, Germany). At least 
10 photomicrographs were randomly taken from each slide 
with at 40× objective. Polynucleolated and total cells were 
counted in every microscopic filed by two observers in a 
blind fashion. The percentage was calculated as (polynu-
cleolated cells/total cells)*100.
Percentage of apoptotic cells
For evaluation of apoptotic cells, HCT- 8 and HCT- 8/R 
were cultured on histological slides both in the absence 
and in the presence of doxorubicin (2 × IC50, 4.10
−7 and 
2.10−6, respectively, for 24 h). At the end of treatments, 
specimens were fixed in 4% formaldehyde (freshly prepared 
from paraformaldehyde as normally used for experiments 
in optical microscopy) in 0.1 mol/L phosphate buffer, 
pH 7.4, for 10 min and stained with hematoxylin–eosin. 
The cells were observed in a microscope as described 
above. At least 10 photomicrographs were randomly taken 
from each slides at 100× objective. Apoptotic cells were 
identified as described in Caderni et al [9]. by two observ-
ers in a blind fashion. The percentage of apoptotic cells 
was calculated as: (apoptotic cells/total cells)*100.
Transcriptome analysis
Total RNA was extracted using the RNeasy Mini kit 
(Qiagen, Milan, Italy); RNA concentration and purity was 
determined by using a NanoPhotometer spectrophotometer 
(IMPLEN) and the RNA integrity (RIN) checked with a 
2100 Bioanalyzer and a RNA 6000 Nano LabChip kit 
(Agilent Technologies). The labeling and hybridization 
steps were carried out according to the Agilent protocol 
(Two- Color Microarray- Based Gene Expression Analysis 
version 5.7), using a two- color design in which HCT- 8/R 
cells were contrasted within parental HCT- 8.. The labeled 
samples were hybridized to Agilent Human GE 4 × 44K 
microarray in Agilent microarray chambers (G2534A) at 
65° for 18 h. GE arrays were scanned using a Genepix 
4000B microarray scanner at 5- μm resolution (Axon 
Instruments, Foster City, CA, USA). Image analysis and 
initial quality control were performed using the Agilent 
Feature Extraction Software v9.5. Differentially genes were 
identified by t- test, comparing normalized red (HCT- 8/R) 
versus green (parental HCT- 8) signals. Pathways analysis 
was performed using GO- elite version 1.2 beta (http://
www.genmapp. org/go_elite).
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Real- time PCR
RNA from HCT- 8/R and HCT- 8 cells were retrotranscribed 
using 100 units of SuperScriptTM II Reverse Transcriptase 
(Life Technologies) and 1× random examers (Roche 
Diagnostics, Monza, Italy). The amplification reactions 
were conducted in a volume of 20 μL containing 1× 
Quantitect SYBR Green master mix (Qiagen, Valencia, 
CA, USA) in a 7900HT Applied Biosystems instrument. 
Reactions were carried out in the presence of specific 
primers for ATP- binding cassette, sub- family B, member 
1, ABCB1 (5′- AGGAAGCCAATGCCTATGACTTTA- 3′ and 
5′- CAACTGGGCCCTCTCTCTC- 3′; NM_000927), caspase 
3, CASP3 (5′- CCGTGAGGAGTTAGCGAGC- 3′ and 5′ 
TCCAGAGTCCATTGATTCGCT- 3′; NM_004346.3), cyc-
lin D1, CCND1 (5′- GATGCCAACCTCCTCAACGA- 3′ and 
5′- GGAAGCGGTCCAGGTAGTTC- 3′; NM_053056.2) or 
for the housekeeping gene glyceraldehyde 3- phosphate 
dehydrogenase, GAPDH, used as a constitutive control 
for normalization.
Relative quantification of mRNA expression was carried 
out using the Delta Delta Ct (2−ΔΔCT) method (Schmittgen 
and Livak, 2008).
Flow cytometry Pgp detection
P- glycoprotein expression was evaluated by flow cytometry 
analysis. The cells were fixed with 70% methanol for 1 min 
at room temperature, then washed twice with PBS/BSA. The 
cells were incubated with a specific antiserum anti- Human 
MDR- 1 P- Glycoprotein P- gp (Chemicon Millipore Corpora-
tion, Billerica, MA) used at 1 μg per 5 × 105 cells for 
30 min at room temperature, then washed twice with PBS 
and detected using fluorescein isothiocyanate (FITC)- 
conjugated rabbit F(ab’)2 anti- mouse IgG (AbD Serotec, 
Raleigh, NC). Isotype control was used at identical concen-
tration to the P- glycoprotein antibody. Data (10,000 events) 
were acquired in the list mode on a FACScan flow cytometer 
(Becton- Dickinson, San Jose, CA), equipped with a 488 nm 
argon laser and supported a software FACSDIVA. Fluorescence 
emission was collected after passing through band pass filter 
530 nm for FITC. Data collected were analyzed using WinMDI 
2.9 software. P- gp grading was based on median cell fluo-
rescence (MFI) and percentage of cells staining. P- gp expres-
sion levels were determined by the ratio of the value of 
mean fluorescence intensity of the treated (MFIT) with the 
value of mean fluorescence intensity of control (MFIC).
Rhodamine 123 efflux assay
The resistant subline, HCT- 8/R was tested for the activity of 
P- gp protein using the fluorescent dye accumulation assay. 
Suspensions of parental and resistant logarithmic phase cells 
were obtained by trypsinization of monolayer cells. During 
the accumulation period, two aliquots of cells at a density 
of 5 × 105 cell/mL were resuspended in DMEM with 10% 
FCS and 5 μmol/L rhodamine 123 (Sigma, Milan, Italy), and 
incubated at 37°C in a humidified atmosphere of 5% CO2 
for 30 min. After accumulation, efflux was initiated by sedi-
mentation at 1200 rpm and resuspension in rhodamine- free- 
medium. The efflux was carried out at 37°C in 5% CO2 for 
30 min with sampling time at 5, 10, 15, and 30 min. At 
the end of both accumulation and efflux times, cells were 
sedimented, washed twice in ice- cold phosphate- buffered saline 
(PBS), placed in PBS on ice, and kept in the dark until flow 
cytometer analysis. Samples were analyzed by FACSCanto 
flow cytometer (Becton- Dickinson) equipped with a 488 nm 
argon laser. The fluorescence of rhodamine 123 was collected 
by a 530 nm band pass filter. Samples were gated on forward 
scatter versus side scatter to exclude cell debris and clumps. 
A minimum of 10,000 events were collected for each sample 
and analyzed by WinMDI 2.9 software (http://en.bio-soft.net/
other/WinMDI.html).
Immunocytochemistry
HCT- 8 wild- type and HCT- 8/R cells were cultured on his-
tological specimens. After 24 h of culture, cells were fixed 
in 4% formaldehyde in 0.1 mol/L phosphate buffer, pH 7.4, 
for 10 min. The specimens were preincubated in 0.1% (v/v) 
Triton (Sigma Aldrich) and 1% (w/v) bovine serum albumin 
(Sigma Aldrich) in PBS for 15 min at room temperature. 
The cells were incubated with primary antibody anti- Human 
MDR- 1 P- Glycoprotein P- gP (Chemicon Millipore 
Corporation) at final dilution of 1:20 overnight at 4°C. 
Immunoreaction was revealed by using the secondary anti-
body Alexa Fluor 488 rabbit anti- mouse (Invitrogen, San 
Diego, CA) 1:200 for 2 h at room temperature. At least 10 
microscopic fields were randomly taken for each specimen. 
Measurement of the optical density of P- gp- immunosatined 
cells was carried out using the ImageJ 1.33 free- share image 
analysis software (http://rsb.info.nih.gov/ij).
Doxorubicin uptake
For evaluation of intracellular content of doxorubicin, 
HCT- 8 and HCT- 8/R were cultured on histological slides 
and treated for 2 h with 10−5mol/L doxorubicin. At the 
end of the treatment, slides were fixed as described above 
and observed by fluorescence microscopy (Labophot- 2 
Nikon, Japan). Ten photomicrographs were randomly taken 
for each sample and fluorescence was measured using ImageJ 
1.33 image analysis software (http://rsb.info.nih.gov/ij).
Cell migration and cell invasion
A modified Boyden chamber (48- multiwell plates; 
Neuroprobe) was used [10, 11]. Polyvinyl pyrrolidone- free 
5© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
In Vitro Model of MDR Colorectal CancerL. Cinci et al.
polycarbonate filters, 5 μm pore size, were coated with 
100 μg/mL collagen type I and 10 μg/mL fibronectin for 
migration assay and with Matrigel, 0.5 mg/mL (Becton 
Dickinson, Bedford, MA), for cell invasion assay. Medium 
without serum (control) or supplemented with 5% FCS, 
was added to the lower wells, while 12.5 × 103 cells were 
seeded into the upper wells and incubated at 37°C for 
7 h for cell migration, or 24 h for cell invasion. Methanol- 
fixed cells were stained with Diff- Quik (Dade Behring, 
Dudingen, CH) and cell migration/invasion was measured 
by microscopic evaluation of the number of cells moved 
across the filter, in 10 randomly selected fields at mag-
nification 400×. Each experimental point was measured 
in triplicate.
Results
Cell line identification
The DNA STR profiling (13 markers + Amelogenin, AMEL) 
matched with the HCT- 8 [HRT- 18] ATCC® CCL- 244™ 
STR with a percent match (EV value) of 0.94. The only 
mismatch was at the AMEL Y locus, the STR profiling 
in fact, falsely genotyped our cancer cell line as obtained 
from a female donor.
CGH array
HCT8 cells were analyzed by a- CGH, contrasted with a 
sample of undamaged DNA from peripheral blood lym-
phocytes. We found only few aberrations on chromosome 
6, and a large deletion on the Y(p)11.2 region encom-
passing the Amelogenin locus, as shown in Figure S1.
Cell cycle analysis
In Table 1 we reported the percentage of cells in the 
cell cycle phases. This analysis highlighted that HCT- 8 
cells have the same pattern of cell cycle distribution 
in the three time points analyzed. The HCT- 8/R showed 
a small percentage of S- phase cells both after 24 and 
72 h. Contrariwise, after 48 h, the resistant clone showed 
a higher percentage of S- phase cells (44.1%). These 
data were concordant with doubling times of HCT- 8 
and HCT- 8/R cells, 27 and 33 h, respectively.
Cross- resistance profiles
The sensitivity of both HCT- 8 lines to a range of chemo-
therapeutic agents was determined. The IC50 values for 
doxorubicin in HCT- 8/S and HCT- 8/R were 47 ± 1.2 
and 478 ± 5.35 nmol/L, respectively (Resistance Fold 
(RF): 10.2). The resistant clone showed a rather high 
resistance even to 5- FU (IC50 HCT- 8/S 2.01 ± 0.15; IC50 
HCT- 8/R 12.72 ± 0.25; RF: 6.4). HCT- 8/R showed no 
resistance to oxaliplatin.
Transcriptome analysis
Among the 14,177 probes that passed the quality- control 
step, 935 (6.6%) genes were significantly up- regulated and 
765 (4.5%) down- regulated in HCT- 8/R cells compared 
to the HCT- 8 parental cells, with a fold change of at least 
±2 (Table S1). The most up- regulated gene in HCT- 8/R 
cells was the carbonyl reductase 1 (CBR1), CD44, several 
families of aldehyde dehydrogenase, and three members 
of the carbonic anhydrase gene family (CA2, CA8, and 
CA13) were also overexpressed. The gene for P- gp, MDR- 
1, was up- regulated 34- fold in HCT- 8/R compared to the 
parental HCT- 8 cell line. It is interesting to note that 
between down- regulated genes we found those related to 
cell cycle such as CCND1 (cyclin D1) and CHES1 (check-
point suppressor 1), RRP22 (RAS related on chromosome 
22) and DRAM (damage- regulated autophagy modulator) 
involved in apoptotic pathway. Pathways analysis confirmed 
the down- regulation of the cell cycle and found an 
up- regulation of the Notch signaling pathway (Table S2).
q- PCR
Q- PCR confirmed the significant up- regulation of ABCB1 
and the down- regulation of cyclin D1 in HCT8/R cells; 
CASP3 gene was selected as an example of differentially 
expressed gene with a relatively low fold change (−1.68); 
however, q- PCR emphasizes its down- regulation in HCT- -
8/R compared to the parental cells (−5 fold).
Table 1. Distribution of HCT- 8 in cell cycle phases. Values represent the percentage of cells in the individual phases for increasing time point from seeding.
Percentage of cells
G0G1 S G2M
24 h 48 h 72 h 24 h 48 h 72 h 24 h 48 h 72 h
HCT- 8 57.5 58.8 57.0 31.3 35.6 37.1 11.2 5.6 5.9
HCT- 8/R 64.8 50.4 65.7 25.6 44.1 30.7 9.6 5.5 3.6
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Percentage of polynucleolated cells
The morphological analysis of semi- thin sections has high-
lighted a significant increase of the number of polynu-
cleolated cells in HCT- 8/R with respect to HCT- 8 expressed 
as percentage of polynucleolated cells/microscopic field 
(Fig. 1 Panel 1).
Ultrastructural analysis
Ultrastructural analysis determined that resistant cells had a 
larger volume than sensitive cells. HCT- 8/R showed a more 
globular appearance with a lower number of evaginations 
of the cytoplasm and a high ratio nucleus/cytoplasm. This 
analysis demonstrated a more complicated ultrastructural 
Figure 1. Panel 1, presence of polynucleolate cells in HCT- 8(A) and HCT- 8/R (B) evaluated in semi- thin sections stained with toluidine blue. The 
percentage of polynucleolate cells are expressed in the graf. *P < 0.05, scale bar = 50 μm. (ten microscopic fields analyzed with an average of 100 
cells; total number of analyzed cells: 1000) Panel 2, ultrastructural images of HCT- 8 and HCT- 8/R. Panel A shows HCT- 8 cells (×6000; scale bar 5 μm). 
Panel B shows HCT- 8/R (×6000; scale bar 5 μm). Panel C higher magnification of a HCT- 8/R cell that shows a vesicular body in the cytoplasm 
(×20,000; scale bar 1 μm). Panel D shows several cytokeratin fibers in HCT- 8/R cells (×20,000; scale bar 1 μm).
1
2
A B
C D
A B
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organization in HCT- 8/R cells (Fig. 1). In fact, we observed 
an increased number of fibers, probably to be interpreted 
as cytokeratin. HCT- 8/R cells showed many multivesicular 
bodies positioned near the plasmatic membrane.
Percentage of apoptotic cells
The percentage of apoptotic cells was evaluated in each 
microscopic field. Apoptotic cells were recognized by the 
presence of apoptotic appearance of nucleus (Fig. 2) in 
HCT- 8 and HCT- 8/R stained with hematoxylin–eosin. No 
difference was found between the percentage of apoptotic 
cells in HCT- 8 and HCT- 8/R in physiological conditions. 
The treatment with Doxorubicin (2 × IC50 for 24 h) 
induced a significant increase of apoptotic cells in HCT- 8 
but not in HCT- 8/R cells.
Flow cytometer evaluation of P- gp 
expression and functionality
P- gp expression and activity were evaluated by flow cytom-
eter in HCT- 8 and HCT- 8/R. The sensitive cells contained 
30% of P- gp- positive cells (Fig. 3). In HCT- 8/R cells, the 
percentage of P- gp- positive cells was 98%. P- gp activity was 
evaluated by rhodamine- 123 assay. Intracellular rhodamine 
fluorescence was measured by flow cytometric analysis. The 
uptake data were collected after 30 min of incubation with 
rhodamine 123 and efflux results were obtained after 30 min 
in rhodamine- free medium. HCT- 8/R had a reduced accu-
mulation of rhodamine 123 with respect to HCT- 8 cells. 
In parallel, in the resistant clone, we observed a greater 
efflux of drug highlighted by the small amount of rhodamine 
remaining in the cells after the efflux period (Fig. 4).
Immunocytochemical analysis for Pgp
The presence of P- gp in HCT- 8 cells was evaluated with 
an immunocytochemical reaction carried out using a 
specific antiserum. HCT- 8 showed a weak labeling. The 
immunoreactivity was significantly higher in HCT- 8/R 
cells, in which the labeling appeared evident and distrib-
uted over the entire cytoplasmic membrane. Quantification 
carried out by densitometry, showed a significant increase 
of fluorescence levels in HCT- 8/R respect to the sensitive 
clone (Fig. 3).
Immunoelectron microscopy for P- gp
The presence and the distribution of P- gp were evaluated 
also by a pre- embedding immunoelectron technique using 
a specific antiserum. In HCT- 8, the labeling was evident 
only in limited portions of the plasma membrane. On 
the contrary, HCT- 8/R showed an intense labeling dis-
tributed in a cluster along rather extended portions of 
cell membrane (Fig. 3). The labeling was absent in cell 
membrane helpings involved in intercellular contacts.
Cellular doxorubicin uptake
In HCT- 8, the autofluorescence of the drug appeared more 
evident respect to resistant cells. In both clones, doxorubicin 
was distributed mainly inside the nucleus, but in HCT- 8/R, 
the labeling was distributed along the cytoplasmic membrane 
(Fig. 4). Quantitative analysis showed a significant decrease 
of doxorubicin content in the resistant clone.
Cell migration and invasion
Under control condition (1% FCS medium), both HCT- 8 
and HCT- 8/R cells were able to migrate, the former being 
more active (54 ± 3.9 and 27 ± 3.2 migrated cells for 
HCT- 8/S and HCT- 8/R, respectively). When cells were 
stimulated to migrate in response to 5% FCS, resistant 
cell migration was significantly higher than that of parental 
cells (Fig. 5). Comparable results were obtained with 
invasion experiments, in which HCT- 8/R had a more 
Figure 2. Evaluation of percentage of apoptotic cells in HCT- 8 and HCT- 8/R, in the presence and in the absence of doxorubicin. The digitalized image 
on the left shows an illustrative cell characterized by apoptotic appearance (presence of round or oval nuclear fragments apoptotic bodies). The 
percentage of apoptotic cells are illustrated in the graph on the right. **P < 0.01.
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aggressive invasive phenotype, characterized by a signifi-
cantly higher cell migration compared to parental cells 
(3.14 ± 0.4 vs. 1.93 ± 0.3 fold increase, for doxorubicin- 
resistant and parental cells, respectively, Fig. 5).
Discussion
Colorectal cancer (CRC) is a serious public health prob-
lem, with more than one million new cases and over a 
Figure 3. Panel 1 shows the expression of the Pgp MDR-1 gene product in HCT- 8 (A) and HCT- 8/R (B) cells. R = ratio between MFI of treated sample 
and isotype control Percentage of cells staining was also reported. Panel 2: immunocytochemistry of immunostained cells with anti- Pgp antibody. The 
upper panel shows the immunoreaction positivity in HCT- 8 (panel A) and HCT- 8/R (panel B). Inserts show higher magnification of illustrative cells in 
which is possible to evaluate the intensity and distribution of immunolabeling. The quantitative results of densitometry are given in the graph below. 
*P < 0.05 (ten microscopic fields analyzed with an average of 100 cells; total number of analyzed cells: 1000) Panel 3: immunoelectron micrographs 
of HCT- 8 immunostained with anti- Pgp antibody. Panel A: HCT- 8, immunoreaction positivity is visible only in a few portions of cytoplasmic membrane 
(black arrow heads), ×15,000. Panel B: HCT- 8/R, immunoreaction positivity appears intense and distributed in large parts of the cytoplasmic 
membrane, ×5000. Panel C: higher magnification of panel B, ×20,000.
1 (A) (B)
2
3
A B C
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Figure 4. Panel 1 shows flow cytometry histograms of the intracellular rhodamine- 123 accumulation and efflux: (A) parental HCT- 8 cell line; (B) 
resistant HCT- 8 subline. Panel 2: doxorubicin uptake and distribution evaluated by autofluorescence. The upper panel shows doxorubicin presence 
and distribution in HCT- 8 (A) and HCT- 8/R (B). The first image of each row shows the doxorubicin autofluorescence, the central image shows DAPI 
staining and the third images shows the merge. The quantitative results are given in the graph below. ***P < 0.001 (ten microscopic fields analyzed 
with an average of 100 cells; total number of analyzed cells: 1000).
1 (A) (B)
2
A
B
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half million deaths worldwide each year [12]. Multidrug 
resistance (MDR) profoundly limits the effectiveness of 
currently used chemotherapeutic regimens for many human 
malignancies including CRC [13, 14].
The MDR phenotype is a complex phenomenon since 
numerous factors, beyond the up- regulation of drug efflux 
pumps such as P- gp, affect drug sensitivity. Some of them 
have been reported such as drug activation and inactiva-
tion mechanisms, alterations in drug targets, DNA meth-
ylation, processing of drug- induced damage, and evasion 
of apoptosis [15]. In this view, the strategy to revert 
chemoresistance by solely inhibiting P- gp might be insuf-
ficient and/or bypassed by the activation of alternative 
biological pathways. Consequently, a multitarget approach 
to overcome chemoresistance might have more chances 
of success. Thus, the aim of our work was to develop 
and deeply characterize a colon cancer cell model display-
ing MDR to be used to test new strategies to revert this 
phenotype.
A MDR phenotype is usually obtained by prolonged 
cell culture in the presence of low doses of chemothera-
peutic drugs (for instance 0.01 and 2 μg/ml 5- FU) [6] 
or through rather complex procedures involving raising 
concentrations of drugs for long periods [16]. In this , 
the HCT- 8- resistant clone was selected by exposing the 
parental cells to a constant doxorubicin concentration for 
three repeated treatment cycles. This selection method 
mimics rather closely the clinical practice involving the 
appearance of chemoresistant clones after few cycles of 
treatment with single doses.
The resistant phenotype was induced by using doxo-
rubicin as a typical P- gp substrate and to exploit its 
autofluorescence to follow its intra- and extracellular 
movements.
First, we identified our cell line as HCT- 8 by DNA 
STR profiling with a percent match higher than 80%. 
The only mismatch was at the AMEL Y locus, a region 
reported sometimes as deleted [17] a CGH analysis per-
formed on our cell line, pointed out a large deletion at 
the Y(p)11.2 region encompassing the AMEL locus.
To further characterize our HCT- 8/R clone, we evalu-
ated its doubling time and cell cycle distribution; the 
resistant HCT- 8 subclone showed a doubling time longer 
than HCT- 8 parental cells and a rather variable percent-
age of S phase cells indicating an irregular duplication 
rate. Moreover, HCT- 8/R showed a marked increase in 
the percentage of cells in S phase after 48 h from seeding 
suggesting a duplication rate characterized by temporally 
circumscribed pulses.
Several biological phenomena connected with cancer 
such as metastasis could be evaluated in an ecological 
vision [18]; the S phase distribution of HCT- 8/R cells 
could be compatible with a Darwinian selection of a clone 
equipped with survival strategies aimed at decreasing the 
probability of the coexistence of replicative events in the 
presence of cytotoxic drugs. These data are supported by 
those from trascriptomic analysis that shows how the 
HCT- 8/R presented a down- regulations of genes encoding 
for proteins such as cyclin D1, involved in the cell cycle. 
Cyclin D1, in particular, controls the G1/S- phase transi-
tion and its overexpression is associated with the increase 
in radiation- induced apoptosis [19].
The HCT- 8/R cells are not only resistant to doxorubicin, 
but also to 5- FU, whereas they are sensitive to oxaliplatin; 
the overexpression of efflux pumps such as P- gp (up- 
regulated in HCT- 8/R compared to the parental HCT- 8 
cell line) is one of the most important mechanisms involved 
in the resistance to both 5- FU and doxorubicin [20]. On 
the contrary, resistance to oxaliplatin is mediated by other 
transporters such as ATP7A and ATP7B [21], genes that 
are not actually modified in HCT- 8/R.
The analysis carried out by transmission electron micros-
copy revealed a significant increase in cell volume in 
HCT- 8/R compared to the parental cells and the presence 
of cytokeratin fibers and vesicular bodies. These morpho-
logical phenomena could be correlated with an increased 
efflux of exogenous substances such as cytotoxic drugs. 
Morphologically, HCT- 8/R showed a higher percentage 
of polynucleolated cells in comparison to the HCT- 8 cells. 
The presence of more than a nucleolus per cell may be 
Figure 5. Functional characterization of HCT- 8/R cells. Cells were let to migrate (A) or to invade (B) in response to 5% FCS medium. Results are 
reported as increase over control (1% FCS medium). *P < 0.05, **P < 0.01 versus parental cells.
A B
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the indication of an adaptive process aimed to counteract 
nucleolus damages induced by doxorubicin. Ultrastructural 
studies showed the occurrence of doxorubicin nucleolar 
segregation in rat liver and heart cells [22], and Abe and 
coworkers found considerable alterations in the nucleolar 
morphology and function on Hela cells treated with doxo-
rubicin. This treatment also induced a dramatic reduction 
of nucleolar 45S ribosomal precursor RNA biosynthesis 
[23]. Moreover, recent findings show that changes in 
nucleolar morphology is related to cellular activity, such 
as growth, proliferation, and cell cycle progression [24]. 
Cancer cells require continuous ribosome biogenesis and 
protein translation to maintain their high proliferation 
rate. In rapidly proliferating cancer cells, nucleolar proteins, 
which are involved in rRNA synthesis and processing, 
become more abundant, leading to nucleolar hypertrophy 
[25]. Our resistant cells showed a longer doubling time 
than that of parental cells and a particular cell- cycle phase 
distribution. The coexistence of polynucleolated cells and 
a lower proliferation rate in our model may be justified 
in the context of the complexity of MDR phenotype.
In fact, it is possible to hypothesize that on one hand, 
the lower proliferation rate observed in resistant cells 
might give an evolutionary advantage in the presence of 
an antineoplastic drug, but on the other hand, the same 
cells MDR cells might benefit from their supernumerary 
nucleoli to counteract chemotherapy- induced nucleolar 
damages. In addition to cancer cells, a large nucleolus is 
a characteristic feature of stem cells and progenitor cells 
[24]. The presence of polynucleolated cells in our model 
may be thus in concordance with their overexpression of 
stem cells markers such as CD44 and aldehyde 
dehydrogenase.
The MDR phenotype observed in the HCT- 8/R appears 
to be also related to their ability to evade the apoptotic 
process; the resistant clone in fact shows a lower percent-
age of apoptotic cells in comparison to parental cells after 
treatment with doxorubicin. In our data, doxorubicin 
doubled the percentage of apoptotic cells in parental clone, 
but did not change the basal level of apoptotic cells in 
HCT- 8/R. In the complexity of the MDR phenotype, these 
data are of particular interest since they indicate that 
resistant cells are able to escape the drug effect not only 
by extracellular efflux mediated by P- gp overexpression 
but also by several other biological mechanisms such as 
a sort of apoptotic “immunity”. Indeed, we found several 
genes involved in the apoptotic process differentially 
expressed in HCT- 8/R cells compared to the HCT- 8 such 
as RAS related on chromosome 22 (RRP22) that promotes 
caspase- independent cell death, damage- regulated 
autophagy modulator (DRAM), and inositol 
polyphosphate- 5- phosphatase (INPP5D), involved in the 
promotion of apoptosis through p53 pathway [26–28]. 
To further support the involvement of apoptosis “immu-
nity” in the complex phenomenon of MDR, our q- PCR 
data confirmed that caspase 3, a key gene involved in 
the apoptotic pathway, was down- regulated in HCT- 8/R 
compared to parental cells. Of note, the MDR phenotype 
was also be associated with the appearance of stem cell 
features such as a significant overexpression of the well- 
known stem cells markers CD44 and aldehyde dehydro-
genase 1 family member A2 (ALDH1A2). This aspect, 
together with the increased capacity of migration and 
invasion suggest that the HCT- 8/R clone may mimic a 
more aggressive form of colorectal cancer. Pasqualato and 
coworkers reported that the migration and invasion capac-
ity was related to several morphological parameters such 
as area- perimeter ratio, circularity, and deformability [29]. 
HCT- 8/R showed a greater volume and a higher nucleus–
cytoplasm ratio as well. The analysis of migration and 
invasion capacity was included in the characterization of 
our MDR cells because even if these traits are not directly 
involved in the onset of chemoresistance, they represent 
an additional aggressive feature which characterized our 
clone. Previous observations suggested that the acquisition 
of the multidrug resistance phenotype is associated with 
elevated invasion and metastasis that might be linked with 
P- gp overexpression [30].
The most well- known mechanism of drug resistance is 
the up- regulation of ATP- binding cassette (ABC) trans-
porters, such as P- gp [20]. As mentioned before, the 
HCT- 8/R clone exhibited a 34- fold overexpression of the 
gene encoding for the P- gp pump. The increased expres-
sion of Pgp on cell membrane was confirmed by cyto-
fluorimetric and immunocytochemical analysis. 
Immune- electron microscopy, in particular, shed light into 
a peculiar distribution of P- gp that is located in clusters 
along the cell membrane not involved in cell–cell junc-
tions. The cytofluorimetric analysis and the quantification 
of doxorubicin autofluorescence, indicated an increased 
activity of Pgp in HCT- 8/R. In resistant cells, doxorubicin 
is located on cell membrane and it is almost absent inside 
the nucleus compared to parental cells. This peculiar dis-
tribution is compatible with the binding of doxorubicin 
with the increased number of efflux pumps such as P- gp, 
in the membrane layer.
Another important mechanism involved in the onset 
of MDR phenotype is hypoxia. In fact, in response to 
tumor hypoxia, cells undergo adaptive modifications that 
promote their survival and intratumoral hypoxia is closely 
associated with increased resistance to conventional chemo-
 and radiotherapies [31]. It is interesting to note that 
the most up- regulated gene (+497 fold) in HCT- 8/R cells 
was the carbonyl reductase 1 (CBR1), a NADPH- dependent 
enzyme that catalyzes a large number of endogenous and 
pharmacological substrates, reported to be up- regulated 
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in response to HIF- 1α and to be able to protect cancer 
cells against hypoxia and anticancer drugs such as cisplatin 
and doxorubicin, by reducing oxidative stress [32, 33]. 
Moreover, in HCT- 8/R cells, a modest up- regulation of 
three carbonic anhydrases (CA2, CA8, and CA13) involved 
in cellular hypoxia- induced response were also observed.
In conclusion, because of its peculiar characteristics of 
cell cycle distribution, apoptosis, morphology, stem cells 
markers, migration, and invasion, our in vitro model is 
able to mimic an aggressive colorectal cancer with a MDR 
phenotype. These features make the HCT- 8/R clone par-
ticularly useful for the study of the mechanisms underlying 
the MDR and for testing new pharmacological strategies 
to overcome this phenomenon.
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